The latest price target for HCA Healthcare (NYSE:HCA) was reported by Barclays on November 8, 2024. The analyst firm set a price target for $392.00 expecting HCA to rise to within 12 months (a possible 19.84% upside). 47 analyst firms have reported ratings in the last year.

The latest analyst rating for HCA Healthcare (NYSE:HCA) was provided by Barclays, and HCA Healthcare maintained their overweight rating.

There is no last upgrade for HCA Healthcare

The last downgrade for HCA Healthcare Inc happened on January 4, 2024 when Bernstein changed their price target from N/A to $301 for HCA Healthcare Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of HCA Healthcare, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for HCA Healthcare was filed on November 8, 2024 so you should expect the next rating to be made available sometime around November 8, 2025.

While ratings are subjective and will change, the latest HCA Healthcare (HCA) rating was a maintained with a price target of $396.00 to $392.00. The current price HCA Healthcare (HCA) is trading at is $327.11, which is out of the analyst’s predicted range.